Ezetimibe/Pitavastatin Calcium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ezetimibe/Pitavastatin Calcium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ezetimibe/Pitavastatin Calcium can convert its Small molecule drug profile and CETP x HMGCR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ezetimibe/Pitavastatin Calcium (query alias: Ezetimibe/Pitavastatin Calcium) |
|---|---|
| Modality / target | Small molecule drug; CETP x HMGCR; CETP inhibitors, HMG-CoA reductase inhibitors |
| Highest global status | Approved |
| Originator | Kowa Co., Ltd. |
| Active developers | Kowa Co., Ltd., Addpharma, Inc., JW PHARMACEUTICAL Corp. |
The MCP disease footprint includes Hypercholesterolemia, Hypercholesterolemia, Familial, Primary hypercholesterolemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07605130 | Phase 4 | Not yet recruiting | 420 | Change from baseline in composite cognitive Z-score at week 24 |
| CTR20261598 | Not Applicable | 进行中 （尚未招募） | 72 | Not disclosed |
| CTR20261439 | Not Applicable | 已完成 | 40 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia
Phase 3; n=301; evaluation: not stated. Reported fields: Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56(Mean): Difference in Means = -56.7(95% CI, -64.3 to -49.0), P-Value = <0.001; Difference in Means = -36.0(95% CI, -41.8 to -30.2), P-Value = <0.001; Difference in Means = -28.1(95% CI, -33.6 to -22.6), P-Value = <0.001; Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56(Mean) = -64.6 Percent Change (95% Confidence Interval, -68.3 to -60.9); Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56(Mean): Difference in Means = -56.7(95% CI, -64.3 to -49.0), P-Value = <0.001; Difference in Means = -36.0(95% CI, -41.8 to -30.2), P-Value = <0.001; Difference in Means = -28.1(95% CI, -33.6 to -22.6), P-Value = <0.001
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Phase 4; n=108; evaluation: Positive. Reported fields: LDL-C(2-week) = 63.0 mg/dL ( 17.0); LDL-C(2-week) = 31.0 mg/dL ( 16.0)
《柳叶刀》：口服新药使 “坏胆固醇” 额外降低近50%，超70%患者降脂达标！
临床3期; n=407; evaluation: 积极. Reported fields: LDL-C: Difference (%) = -48.6(95% CI, -58.3 ~ -38.9); Difference (%) = -27.9(95% CI, -37.5 ~ -18.4); Difference (%) = -16.8(59% CI, -26.4 ~ -7.1); LDL-C: Difference (%) = -48.6(95% CI, -58.3 ~ -38.9); Difference (%) = -27.9(95% CI, -37.5 ~ -18.4); Difference (%) = -16.8(59% CI, -26.4 ~ -7.1); LDL-C: Difference (%) = -48.6(95% CI, -58.3 ~ -38.9); Difference (%) = -27.9(95% CI, -37.5 ~ -18.4); Difference (%) = -16.8(59% CI, -26.4 ~ -7.1)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ezetimibe/Pitavastatin Calcium addresses Hypercholesterolemia, Hypercholesterolemia, Familial, Primary hypercholesterolemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CETP x HMGCR records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-06-28 | NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe | Phase 3 | US$150.5M upfront; US$911.4M milestones; US$1,061.9M stated total |
| 2020-08-25 | NewAmsterdam Pharma Acquires Obicetrapib from Amgen | Phase 2 | Financial terms not disclosed |
| 2017-12-12 | NorthSea Therapeutics secures €25 million funding for clinical development of promising NASH drug licensing from Pronova BioPharma | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
